AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study …,

(NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s drug Ampligen as an …, (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s drug Ampligen as an …, Read More

Scroll to Top